

# Ahwon Jeong

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8202336/ahwon-jeong-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8

papers

113

citations

5

h-index

8

g-index

8

ext. papers

164

ext. citations

3.7

avg, IF

2.37

L-index

#	Paper	IF	Citations
8	Natural Killer Cell IFN $\gamma$ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3747-3754	3.1	41
7	A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 178, 327-335	4.4	33
6	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 142, 132-140	7.5	20
5	Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 925-943	3.9	10
4	Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 178, 347-356	4.4	6
3	Health Outcomes of Immigrants in Nursing Homes: A Population-Based Retrospective Cohort Study in Ontario, Canada. <i>Journal of the American Medical Directors Association</i> , <b>2020</b> , 21, 740-746.e5	5.9	2
2	Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , <b>2021</b> , 28, 1847-1856	2.8	1
1	Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e24083-e24083	2.2	0